info@seagull-health.com
SeagullHealth
search
ORENCIA(Abatacept)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
ORENCIA(Abatacept) Instructions:Uses,Dosage, Side Effects
ORENCIA (abatacept) is an immunomodulatory biologic agent designed to treat autoimmune diseases by selectively modulating T-cell activation. Its unique mechanism involves inhibiting the CD80/CD86-CD28 costimulatory signal required for T-cell activation, helping reduce inflammation and prevent further tissue damage in diseases like rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis. It is also used as a prophylactic measure for acute graft-versus-host disease (aGVHD) in patients undergoing hematopoietic stem cell transplantation.
ORENCIA can be administered either intravenously or subcutaneously, with dosing tailored to the patient's and condition. The drug provides critical therapeutic benefits in the management of chronic autoimmune conditions and plays an essential role in transplant-related complications. Regular monitoring of patients is recommended due to potential adverse effects, including infections and hypersensitivity reactions.
ORENCIA is indicated for the treatment of: Adults with moderately to severely active rheumatoid arthritis (RA);Pediatric patients ≥2 years of age with moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA);Adults and pediatric patients ≥2 years of age with active psoriatic arthritis (PsA);Prophylaxis of acute graft-versus-host disease (aGVHD) in patients ≥2 years undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1-allele mismatched unrelated donor, in combination with a calcineurin inhibitor and methotrexate.
1. For RA and PsA (Adults, IV Use):
1.1 Administer at Weeks 0, 2, and 4, then every 4 weeks
1.2 Dosage by body weight:<60 kg: 500 mg (2 vials);60–100 kg: 750 mg (3 vials);100 kg: 1,000 mg (4 vials)
1.3 Infusion time: 30 minutes
1.4 Subcutaneous Use (RA and PsA):125 mg once weekly,IV loading dose optional for RA; not required for PsA
2. For pJIA (≥6 years, IV Use):<75 kg: 10 mg/kg;≥75 kg: Adult dosing
2.1 Administer on Days 0, 14, 28, then every 4 weeks
2.2 Subcutaneous Use (pJIA/PsA, ≥2 years):10–<25 kg: 50 mg;25–<50 kg: 87.5 mg;≥50 kg: 125 mg
2.3 Weekly administration:aGVHD Prophylaxis (IV):≥6 years: 10 mg/kg (max 1,000 mg) on Day –1, +5, +14, +28;2–<6 years: 15 mg/kg (Day –1), 12 mg/kg (Days +5, +14, +28)
2.4 Infusion time: 60 minutes
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
